Tamoxifen Metabolite Concentrations, CYP2D6 Genotype, and Breast Cancer Outcomes
Top Cited Papers
- 23 March 2011
- journal article
- research article
- Published by Wiley in Cancer Cell
- Vol. 89 (5), 718-725
- https://doi.org/10.1038/clpt.2011.32
Abstract
We explored whether breast cancer outcomes are associated with endoxifen and other metabolites of tamoxifen and examined potential correlates of endoxifen concentration levels in serum including cyto...Keywords
This publication has 28 references indexed in Scilit:
- The Impact of CYP2D6 Genotyping on Tamoxifen TreatmentPharmaceuticals, 2010
- Genotype-guided tamoxifen therapy: time to pause for reflection?The Lancet Oncology, 2009
- Time-Varying Effects of Prognostic Factors Associated With Disease-Free Survival in Breast CancerAmerican Journal of Epidemiology, 2009
- Hazard of recurrence and adjuvant treatment effects over time in lymph node-negative breast cancerBreast Cancer Research and Treatment, 2008
- Influence of a Diet Very High in Vegetables, Fruit, and Fiber and Low in Fat on Prognosis Following Treatment for Breast CancerJAMA, 2007
- Tamoxifen, hot flashes and recurrence in breast cancerBreast Cancer Research and Treatment, 2007
- Effects of Estrogen Receptor Expression and Histopathology on Annual Hazard Rates of Death from Breast CancerBreast Cancer Research and Treatment, 2006
- CYP2D6 Genotype, Antidepressant Use, and Tamoxifen Metabolism During Adjuvant Breast Cancer TreatmentJNCI Journal of the National Cancer Institute, 2005
- Active Tamoxifen Metabolite Plasma Concentrations After Coadministration of Tamoxifen and the Selective Serotonin Reuptake Inhibitor ParoxetineJNCI Journal of the National Cancer Institute, 2003
- Metabolites of tamoxifen in animals and man: Identification, pharmacology, and significanceBreast Cancer Research and Treatment, 1982